

FORM 9

NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

(or securities convertible or exchangeable into listed securities¹)

Name of Listed Issuer:

Symbol(s):

Asep Medical Holdings Inc. (the "Issuer").	ASEP
--	------

Date: April 30, 2026 Is this an updating or amending Notice: ☒ Yes ☐ No

If yes provide date(s) of prior Notices: April 29, 2026.

Issued and Outstanding Securities of Issuer Prior to Issuance: 15,873,520.

Pricing

Date of news release announcing proposed issuance: April 29, 2026 or

Date of confidential request for price protection: N/A

Closing Market Price on Day Preceding the news release: \$0.31 or

Day preceding request for price protection: N/A

Closing

Number of securities to be issued: The Issuer has agreed to offer up to \$200,000 Principal amount of convertible debentures (each, a "Debenture") at market price on the closing date pursuant to a non-brokered private placement (the "Offering"). The Debentures bear interest at a rate of 12% per annum and mature one year following the issue date of the Debentures (the "Maturity Date"). The Issuer closed a final tranche of the Offering on March 10, 2026 (the "Final Tranche") and issued 200 Debentures.

Issued and outstanding securities following issuance: 15,873,520

Instructions:

1. For private placements (including debt settlement), complete tables 1A and 1B in Part 1 of this form.
2. Complete Table 1A – Summary for all purchasers, excluding those identified in Item 8.
3. Complete Table 1B – Related Persons only for Related Persons
4. If shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition) please proceed to Part 2 of this form.

5. An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10 – Notice of Proposed Transaction
6. Post the completed Form 9 to the CSE website in accordance with *Policy 6 – Distributions*. In addition, the completed form must be delivered to listings@thecse.com with an appendix that includes the information in Table 1B for ALL placees.

Part 1. Private Placement

Table 1A – Summary

Each jurisdiction in which purchasers reside	Number of Purchasers	Price per Security	Total dollar value (CDN\$) raised in the jurisdiction
TBD	1	\$1,000 per Debenture	CA\$200,000
Total number of purchasers:	1		
Total dollar value of distribution in all jurisdictions:			CA\$200,000

Table 1B – Related Persons

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date ⁽¹⁾	Describe relationship to Issuer ⁽²⁾
N/A							

¹An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: CA\$200,000 .
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. General working capital purposes .
3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: N/A .

4. If securities are issued in forgiveness of indebtedness, provide details of the debt agreement(s) or and the agreement to exchange the debt for securities.

5. Description of securities to be issued:

(a) Class N/A_____.

(b) Number N/A_____.

(c) Price per security N/A_____.

(d) Voting rights N/A_____.

6. Provide the following information if warrants, (options) or other convertible securities are to be issued:

(a) Number N/A_____.

(b) Number of securities eligible to be purchased on exercise of warrants (or options) N/A_____.

(c) Exercise price N/A_____.

(d) Expiry date N/A_____.

7. Provide the following information if debt securities are to be issued:

(a) Aggregate principal amount CA\$200,000_____.

(b) Maturity date One year from the date of issuance of the Debentures_____.

(c) Interest rate 12% per annum_____.

(d) Conversion terms At the sole option of the subscriber, the principal amount of the Debentures and accrued interest thereon may be converted into common shares in the capital of the Issuer (each, a "Share") at a conversion price equal to the market price on the closing date (the "Conversion Price"), subject to adjustment as provided for in the certificate representing the Debenture (the "Debenture Certificate").

(e) Default: The occurrence of any of the following will constitute an "Event of Default" under the Debentures:

• the Issuer failing to pay the principal amount on the Maturity Date;

• any representation or warranty made by the Issuer in this Debenture Certificate being found to be false or incorrect in any way so as to make it materially misleading when made;

• the Issuer failing to observe or perform any covenant or agreement contained in the Debenture Certificate which failure is not cured, if possible to cure, within 30 business days after notice of such default is sent by the subscriber to the Issuer;

• the Issuer: (i) applying for or consenting to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a substantial part of its property, (ii) making a general assignment for the benefit of its or any of its creditors, (iii) being dissolved or liquidated in full or in part, (iv) commencing a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect, or consenting to any such relief, or to the appointment of, or taking possession of its property by, any official in an involuntary case or other proceeding commenced against it, or (v) taking any action for the purpose of effecting any of the foregoing; and

• the Issuer entering into any proceeding for the appointment of a receiver, trustee, liquidator or custodian of the issuer or of all or a substantial part of the property thereof, or an involuntary case or other proceeding seeking liquidation, reorganization or other relief with respect to the Issuer or the debts thereof under any bankruptcy, insolvency or other similar law now or hereafter in effect is commenced and an order for relief is not entered or such proceeding is not dismissed or discharged within 30 business days of commencement.

8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.): N/A

(a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): _____ .

(b) Cash _____ .

(c) Securities _____ .

(d) Other _____ .

(e) Expiry date of any options, warrants etc. _____ .

(f) Exercise price of any options, warrants etc. _____ .

9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship _____

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF
LISTED SECURITIES**

-
10. Describe any unusual particulars of the transaction (i.e. tax “flow through” shares, etc.).
- N/A
11. State whether the private placement will result in a change of control or if the issuance will materially affect control of the Issuer.
- N/A
12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. N/A.
13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102 Resale of Securities.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. the Issuer has obtained the express written consent of each applicable individual to:
 - (a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and
 - (b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time
4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
5. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated April 30, 2026.

Jacqueline Tucker
Name of Director or Senior
Officer

/s/ Jacqueline M. Tucker
Signature

Chief Financial Officer
Official Capacity

Appendix A

PERSONAL INFORMATION COLLECTION POLICY REGARDING FORM 9

The Canadian Securities Exchange and its subsidiaries, affiliates, regulators and agents (collectively, “CSE or the “Exchange”) collect and use the information (which may include personal or other information) which has been provided in Form 9 for the following purposes:

-
- To determine whether an individual is suitable to be associated with a Listed Issuer;
- To determine whether an issuer is suitable for listing;
- To determine whether allowing an issuer to be listed or allowing an individual to be associated with a Listed Issuer could give rise to investor protection concerns or could bring the Exchange into disrepute;
- To conduct enforcement proceedings;
- To ensure compliance with Exchange Requirements and applicable securities legislation; and
- To fulfil the Exchange’s obligation to regulate its marketplace.

The CSE also collects information, including personal information, from other sources, including but not limited to securities regulatory authorities, law enforcement and self-regulatory authorities, regulation service providers and their subsidiaries, affiliates, regulators and agents. The Exchange may disclose personal information to these entities or otherwise as provided by law and they may use it for their own investigations.

The Exchange may use third parties to process information or provide other administrative services. Any third party will be obliged to adhere to the security and confidentiality provisions set out in this policy.

All personal information provided to or collected by or on behalf of The Exchange and that is retained by The Exchange is kept in a secure environment. Only those employees who need to know the information for the purposes listed above are permitted access to the information or any summary thereof. Employees are instructed to keep the information confidential at all times.

Information about you that is retained by the Exchange and that you have identified as inaccurate or obsolete will be corrected or removed.

If you wish to consult your file or have any questions about this policy or our practices, please write the Chief Privacy Officer, Canadian Securities Exchange, 220 Bay Street – 9th Floor, Toronto, ON, M5J 2W4.